Korro Bio, Inc./$KRRO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Korro Bio, Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Ticker
$KRRO
Sector
Primary listing
Employees
92
Headquarters
Website
Korro Bio, Inc. Metrics
BasicAdvanced
$410M
-
-$9.76
-
-
Price and volume
Market cap
$410M
52-week high
$49.71
52-week low
$10.29
Average daily volume
258K
Financial strength
Current ratio
5.976
Quick ratio
5.675
Long term debt to equity
36.669
Total debt to equity
38.776
Profitability
EBITDA (TTM)
-93.984
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,454.47%
Operating margin (TTM)
-1,569.08%
Effective tax rate (TTM)
-0.10%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-28.65%
Return on equity (TTM)
-58.34%
Valuation
Price to revenue (TTM)
65.138
Price to book
3.57
Price to tangible book (TTM)
3.57
Price to free cash flow (TTM)
-5.539
Free cash flow yield (TTM)
-18.05%
Free cash flow per share (TTM)
-7.889
Growth
Earnings per share change (TTM)
-35.44%
Bulls say / Bears say
Ended Q1 2025 with $139.0 million in cash, cash equivalents and marketable securities, providing runway into 2027 and supporting continued investment in clinical programs. (GlobeNewswire)
Interim readout from the Phase 1/2a REWRITE clinical trial of KRRO-110 for AATD is on track for the second half of 2025 after global expansion of trial sites, demonstrating robust clinical progress and safety. (GlobeNewswire)
Collaboration revenue of $2.55 million in Q1 2025 from the Novo Nordisk partnership validates Korro’s OPERA™ platform and provides non-dilutive funding to support pipeline expansion. (GlobeNewswire)
Net loss widened to $23.4 million in Q1 2025 from $19.6 million a year earlier, reflecting escalating R&D and operational expenses without product revenues. (GlobeNewswire)
Research and development expenses jumped 45% year-over-year to $19.7 million in Q1 2025, intensifying cash burn risk ahead of pivotal clinical readouts. (GlobeNewswire)
Strategic reduction of approximately 20% of the workforce and related $1.2 million restructuring charges may disrupt execution and underline underlying cost pressures. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Korro Bio, Inc. stock?
Korro Bio, Inc. (KRRO) has a market cap of $410M as of October 07, 2025.
What is the P/E ratio for Korro Bio, Inc. stock?
The price to earnings (P/E) ratio for Korro Bio, Inc. (KRRO) stock is 0 as of October 07, 2025.
Does Korro Bio, Inc. stock pay dividends?
No, Korro Bio, Inc. (KRRO) stock does not pay dividends to its shareholders as of October 07, 2025.
When is the next Korro Bio, Inc. dividend payment date?
Korro Bio, Inc. (KRRO) stock does not pay dividends to its shareholders.
What is the beta indicator for Korro Bio, Inc.?
Korro Bio, Inc. (KRRO) does not currently have a Beta indicator.